Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Key claim: A phase I trial is evaluating the safety, tolerability, and efficacy of olutasidenib as post-allogeneic hematopoietic cell transplant maintenance therapy to prevent relapse in patients with IDH1-mutated AML, MDS, or CMML.
Abstract
This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) carrying an IDH1 mutation. Olutasidenib is in a class of medications called IDH1 inhibitors. It works by slowing or stopping the growth of cancer cells. Giving olutasidenib may be safe, tolerable and/or effective in preventing relapse in patients with IDH1 mutated AML, MDS or CMML after an allogeneic hematopoietic cell transplant.
Why this matters
Post-transplant relapse remains a major cause of failure for CMML and MDS/MPN overlap patients undergoing allogeneic HCT, and mutation-directed maintenance strategies have lagged behind those developed for FLT3- or IDH-mutated AML. This phase I olutasidenib trial is the first prospective evaluation of IDH1-inhibitor maintenance after alloHCT inclusive of IDH1-mutated CMML, potentially establishing a molecularly tailored relapse-prevention option for a subtype where transplant outcomes and post-transplant therapy are poorly standardized.